Welcome to our dedicated page for Quantum BioPharma news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum BioPharma stock.
Quantum BioPharma Ltd. (QNTM) generates news across clinical development, capital markets, licensing, and legal proceedings, reflecting its role as a biopharmaceutical company focused on neurodegenerative and metabolic disorders and alcohol misuse disorders. Many of its recent announcements center on Lucid-21-302 (Lucid-MS), a patented new chemical entity developed through its subsidiary Lucid Psycheceuticals Inc. News items describe progress in toxicity and toxicokinetic studies, Phase 1 clinical work, and preparations for an Investigational New Drug (IND) application with the U.S. FDA, as well as a joint PET imaging study with Massachusetts General Hospital scientists to monitor myelin integrity in multiple sclerosis.
Investors following QNTM news will also see updates on financial results, balance sheet developments, and capital structure changes, including private placements, warrant expirations, at-the-market offering agreements, and the issuance of contingent value rights (CVRs) linked to potential recoveries from litigation. The company’s disclosures highlight its digital asset portfolio, comprised mainly of Bitcoin and other cryptocurrencies, and provide commentary on realized gains and treasury management.
Another recurring theme in Quantum BioPharma’s news flow is its relationship with Unbuzzd Wellness Inc., licensee of the unbuzzd asset. Press releases cover Unbuzzd Wellness Inc.’s capital raising plans, investor webinars, and positioning of unbuzzd as a beverage or supplement aimed at alcohol metabolism and related symptoms, while noting Quantum BioPharma’s equity stake and royalty rights.
In addition, Quantum BioPharma issues updates on its lawsuit alleging stock market manipulation and stock spoofing involving major financial institutions, including coverage by investigative news program W5. These items outline the company’s allegations, the scale of the claimed damages, and the link between the litigation and the CVR structure. For readers and investors, the QNTM news stream offers a consolidated view of clinical milestones, financial reporting, licensing activity, and legal developments related to Quantum BioPharma.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), formerly FSD Pharma Inc., has completed its name change and 65:1 share consolidation. The company's Class B subordinate voting shares will trade under the new ticker symbol 'QNTM' on NASDAQ and CSE. After consolidation, Class B shares reduced from 84,531,149 to approximately 1,300,727, while Class A multiple voting shares decreased from 72 to 2.
The company also closed a non-brokered private placement, issuing 4 post-consolidation Class A Multiple Voting Shares at $18.00 each for gross proceeds of $72.00. Insiders Xorax Family Trust and Fortius Research and Trading Corp. purchased all Class A shares in this offering, which is considered a related-party transaction under MI 61-101.